{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:38:13Z","timestamp":1773661093191,"version":"3.50.1"},"reference-count":74,"publisher":"Impact Journals, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,1,5]]},"DOI":"10.18632\/oncotarget.22751","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T17:30:51Z","timestamp":1511976651000},"page":"1785-1802","source":"Crossref","is-referenced-by-count":13,"title":["Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells"],"prefix":"10.18632","volume":"9","author":[{"given":"Irina A","family":"Tarasova","sequence":"first","affiliation":[{"name":"Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alesya V","family":"Tereshkova","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia"},{"name":"Chumakov Institute of Poliomyelitis and Viral Encephalitides, Russian Academy of Sciences, 142782 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna A","family":"Lobas","sequence":"additional","affiliation":[{"name":"Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia"},{"name":"Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizaveta M","family":"Solovyeva","sequence":"additional","affiliation":[{"name":"Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia"},{"name":"Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena S","family":"Sidorenko","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Gorshkov","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense M, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Kjeldsen","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense M, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia A","family":"Bubis","sequence":"additional","affiliation":[{"name":"Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia"},{"name":"Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark V","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia"},{"name":"Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina Y","family":"Ilina","sequence":"additional","affiliation":[{"name":"Orekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergei A","family":"Moshkovskii","sequence":"additional","affiliation":[{"name":"Orekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia"},{"name":"Pirogov Russian National Research Medical University, 117997 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M","family":"Chumakov","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia"},{"name":"Chumakov Institute of Poliomyelitis and Viral Encephalitides, Russian Academy of Sciences, 142782 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail V","family":"Gorshkov","sequence":"additional","affiliation":[{"name":"Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia"},{"name":"Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","article-title":"Survival in glioblastoma: a review on the impact of treatment modalities","volume":"18","author":"Corrales-Garcia","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"DeAngelis","year":"2013","journal-title":"Jama"},{"key":"3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11060-004-2751-6","article-title":"Molecular mechanisms of glioma cell migration and invasion","volume":"70","author":"Berens","year":"2004","journal-title":"J Neurooncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1038\/onc.2011.466","article-title":"Girdin maintains the stemness of glioblastoma stem cells","volume":"31","author":"Wakabayashi","year":"2012","journal-title":"Oncogene"},{"key":"5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.15252\/emmm.201505890","article-title":"MET inhibition overcomes radiation resistance of glioblastoma stem-like cells","volume":"8","author":"Finocchiaro","year":"2016","journal-title":"EMBO Mol Med"},{"key":"6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Parada","year":"2012","journal-title":"Nature"},{"key":"7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Rich","year":"2006","journal-title":"Nature"},{"key":"8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Wu","year":"2013","journal-title":"Cell"},{"key":"9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4103\/2152-7806.132138","article-title":"Glioblastoma multiforme: State of the art and future therapeutics","volume":"5","author":"Harter","year":"2014","journal-title":"Surg Neurol Int"},{"key":"10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1517\/14728214.2012.679929","article-title":"Recent developments on immunotherapy for brain cancer","volume":"17","author":"Lesniak","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s13311-017-0516-0","article-title":"Oncolytic Virotherapy for the Treatment of Malignant Glioma","volume":"14","author":"Markert","year":"2017","journal-title":"Neurotherapeutics"},{"key":"12","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/mt.2015.109","article-title":"Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer","volume":"23","author":"Burke","year":"2015","journal-title":"Mol Ther"},{"key":"13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4161\/cc.27039","article-title":"Immunovirotherapy for glioblastoma","volume":"13","author":"Rabkin","year":"2014","journal-title":"Cell Cycle"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Kaufmann, Chiocca. Glioma virus therapies between bench and bedside. Neuro Oncol. 2014. https:\/\/doi.org\/10.1093\/neuonc\/not310.","DOI":"10.1093\/neuonc\/not310"},{"key":"15","doi-asserted-by":"publisher","first-page":"e27218","DOI":"10.4161\/onci.27218","article-title":"Immunovirotherapy for the treatment of glioblastoma","volume":"3","author":"Rabkin","year":"2014","journal-title":"Oncoimmunology"},{"key":"16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/PPO.0b013e31824671c9","article-title":"Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates","volume":"18","author":"van den Pol","year":"2012","journal-title":"Cancer J"},{"key":"17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.chom.2014.01.002","article-title":"Viruses for Tumor Therapy","volume":"15","author":"McFadden","year":"2014","journal-title":"Cell Host Microbe"},{"key":"18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ebiom.2016.06.046","article-title":"Oncolytic Viruses: Therapeutics With an Identity Crisis","volume":"9","author":"Bell","year":"2016","journal-title":"EBioMedicine"},{"key":"19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/0141076813494196","article-title":"Live viruses to treat cancer","volume":"106","author":"Pandha","year":"2013","journal-title":"J R Soc Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Bell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Lawler, Speranza, Cho, Chiocca. Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncol. 2016. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2064.","DOI":"10.1001\/jamaoncol.2016.2064"},{"key":"22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00109-016-1453-9","article-title":"Oncolytic viruses-immunotherapeutics on the rise","volume":"94","author":"Bell","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"23","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Todo","year":"2016","journal-title":"Cancer Sci"},{"key":"24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1089\/hum.2015.055","article-title":"Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data","volume":"26","author":"Pesonen","year":"2015","journal-title":"Hum Gene Ther"},{"key":"25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2217\/fon.14.254","article-title":"The role of oncolytic virus immunotherapies to subvert cancer immune evasion","volume":"11","author":"Mossman","year":"2015","journal-title":"Future Oncol"},{"key":"26","doi-asserted-by":"publisher","first-page":"16013","DOI":"10.1038\/mto.2016.13","article-title":"Oncolytic herpes simplex virus kills stem-like tumor-initiating colon cancer cells","volume":"3","author":"Fong","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3978\/j.issn.2306-9759.2014.11.01","article-title":"Targeting cancer stem cells with oncolytic virus","volume":"1","author":"Qian","year":"2014","journal-title":"Stem Cell Investig"},{"key":"28","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3892\/or.2012.2211","article-title":"The oncolytic herpes simplex virus vector G47 effectively targets breast cancer stem cells","volume":"29","author":"Liu","year":"2013","journal-title":"Oncol Rep"},{"key":"29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1479-5876-10-167","article-title":"Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells","volume":"10","author":"Szalay","year":"2012","journal-title":"J Transl Med"},{"key":"30","first-page":"62","article-title":"Oncolytic measles virus strains have significant antitumor activity against glioma stem cells","volume":"23","author":"Galanis","year":"2012","journal-title":"Gene Ther"},{"key":"31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-61779-340-0_9","article-title":"Targeting brain tumor stem cells with oncolytic adenoviruses","volume":"797","author":"Fueyo","year":"2012","journal-title":"Methods Mol Biol"},{"key":"32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1158\/0008-5472.can-12-2221","article-title":"Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus","volume":"73","author":"Buchholz","year":"2013","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12015-010-9132-7","article-title":"Cancer stem cells: the final frontier for glioma virotherapy","volume":"7","author":"Lesniak","year":"2011","journal-title":"Stem Cell Rev"},{"key":"34","doi-asserted-by":"crossref","unstructured":"McKenzie, Zemp, Pisklakova, Narendran, McFadden, Lun, Kenchappa, Kurz, Forsyth. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neuro Oncol. 2015. https:\/\/doi.org\/10.1093\/neuonc\/nou359.","DOI":"10.1093\/neuonc\/nou359"},{"key":"35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/cgt.2013.47","article-title":"Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures","volume":"20","author":"Hoeben","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"36","first-page":"588","article-title":"Use of Newcastle disease virus vaccine (MTH-68\/H) in a patient with high-grade glioblastoma","volume":"281","author":"Bakacs","year":"1999","journal-title":"JAMA"},{"key":"37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/B:NEON.0000021735.85511.05","article-title":"MTH-68\/H oncolytic viral treatment in human high-grade gliomas","volume":"67","author":"Csatary","year":"2004","journal-title":"J Neurooncol"},{"key":"38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncponc0736","article-title":"Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress","volume":"4","author":"Kirn","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/ov.s62461","article-title":"Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy","volume":"4","author":"Markert","year":"2015","journal-title":"Oncolytic Virother"},{"key":"40","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.trecan.2015.10.004","article-title":"Oncolytic viruses: exploiting cancer's deal with the Devil","volume":"1","author":"Diallo","year":"2015","journal-title":"Trends in Cancer"},{"key":"41","doi-asserted-by":"crossref","first-page":"15011","DOI":"10.1038\/mto.2015.11","article-title":"Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficacy","volume":"2","author":"Chumakov","year":"2015","journal-title":"Molecular Therapy - oncolytics"},{"key":"42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/MO:18:1:3","article-title":"Apoptosis and cell growth inhibition as antitumor effector functions of interferons","volume":"18","author":"Sangfelt Strander","year":"2001","journal-title":"Med Oncol"},{"key":"43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Weinberg","year":"2011","journal-title":"Cell"},{"key":"44","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Bell","year":"2000","journal-title":"Nat Med"},{"key":"45","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/ph3020406","article-title":"Deregulation of interferon signaling in malignant cells","volume":"3","author":"Platanias","year":"2010","journal-title":"Pharmaceuticals"},{"key":"46","doi-asserted-by":"publisher","first-page":"e28683","DOI":"10.1371\/journal.pone.0028683","article-title":"Epigenetic silencing of IRF7 and\/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses","volume":"6","author":"Tainsky","year":"2011","journal-title":"PLoS One"},{"key":"47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/978-1-61779-340-0_15","article-title":"Evaluation of innate immune signaling pathways in transformed cells","volume":"797","author":"Barber","year":"2012","journal-title":"Methods Mol Biol"},{"key":"48","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Kroemer","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ni.3311","article-title":"The tumor suppressor PTEN has a critical role in antiviral innate immunity","volume":"17","author":"Yin","year":"2016","journal-title":"Nat Immunol"},{"key":"50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Darnell","year":"2012","journal-title":"Immunity"},{"key":"51","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Harrison","year":"2004","journal-title":"J Cell Sci"},{"key":"52","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1089\/jir.2012.0110","article-title":"Interferons as inducers of apoptosis in malignant cells","volume":"33","author":"Gamero","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Hertzog","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"54","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/1078-0432.ccr-11-0482","article-title":"The two faces of interferon-gamma in cancer","volume":"17","author":"Merlino","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"55","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.coviro.2011.10.008","article-title":"Interferon-stimulated genes andtheir antiviral effector functions","volume":"2011","author":"Rice","journal-title":"Curr Opin Virol"},{"key":"56","doi-asserted-by":"publisher","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","article-title":"Interferome v2.0: an updateddatabase of annotated interferon-regulated genes","volume":"41","author":"Hertzog","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"57","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gku1003","article-title":"STRING v10: protein-protein interaction networks, integrated over thetree of life","volume":"43","author":"Jensen","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"58","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1471-2105-10-48","article-title":"GOrilla: a tool for discovery and visualization of enriched GO termsin ranked gene lists","volume":"10","author":"Yakhini","year":"2009","journal-title":"BMC Bioinformatics"},{"issue":"21","key":"59","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.ccr-14-1860","article-title":"Immune escape mechanisms asa guide for cancer immunotherapy","volume":"2015","author":"Gladney","journal-title":"Clin Cancer Res"},{"key":"60","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bjc.2015.233","article-title":"The roleof JAK\/STAT signalling in the pathogenesis, prognosis andtreatment of solid tumours","volume":"113","author":"Danson","year":"2015","journal-title":"Br J Cancer"},{"key":"61","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1099\/vir.0.82039-0","article-title":"Inhibition of vesicular stomatitis virus infectionin epithelial cells by alpha interferon-induced solublesecreted proteins","volume":"87","author":"Bose","year":"2006","journal-title":"J Gen Virol"},{"key":"62","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature05732","article-title":"TRIM25RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity","volume":"446","author":"Jung","year":"2007","journal-title":"Nature"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Mazza, Pelicci. Is PML a Tumor Suppressor?Front Oncol. 2013; 3:174. https:\/\/doi.org\/10.3389\/fonc.2013.00174.","DOI":"10.3389\/fonc.2013.00174"},{"key":"64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2017.05.033","article-title":"Jak Stat signaling and cancer: Opportunities, benefitsand side effects of targetedinhibition","volume":"451","author":"von Manstein","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"65","doi-asserted-by":"publisher","first-page":"14340","DOI":"10.1038\/ncomms14340","article-title":"Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity","volume":"8","author":"Allison","year":"2017","journal-title":"Nat Commun"},{"key":"66","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"67","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1134\/S1061934815130055","article-title":"Pepxmltk\u2014a format converter for peptide identification results obtained from tandem mass spectrometry data using X! Tandem search engine","volume":"70","author":"Gorshkov","year":"2015","journal-title":"J Anal Chem"},{"key":"68","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nmeth1019","article-title":"Target-decoy search strategy for increased confidencein large-scale protein identifications by mass spectrometry","volume":"4","author":"Gygi","year":"2007","journal-title":"Nat Methods"},{"key":"69","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1021\/pr401026y","article-title":"Empirical multidimensional space for scoring peptide spectrum matches in shotgun proteomics","volume":"13","author":"Gorshkov","year":"2014","journal-title":"J Proteome Res"},{"key":"70","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nbt.1592","article-title":"Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis","volume":"28","author":"Schnitzer","year":"2010","journal-title":"Nat Biotechnol"},{"key":"71","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1039\/b701483j","article-title":"Quantitative shotgun proteomics using a protease with broad specificity and normalized spectral abundance factors","volume":"3","author":"Washburn","year":"2007","journal-title":"Mol Biosyst"},{"key":"72","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1074\/mcp.M500061-MCP200","article-title":"Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein","volume":"4","author":"Mann","year":"2005","journal-title":"Mol Cell Proteomics"},{"key":"73","volume-title":"Appendix F, Choosing a Statistical Test","author":"Motulsky","year":"2014","edition":"3"},{"key":"74","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1021\/pr400045u","article-title":"Assessment and improvement of statistical tools for comparative proteomics analysis of sparse data sets with few experimental replicates","volume":"12","author":"Jensen","year":"2013","journal-title":"J Proteome Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T10:38:15Z","timestamp":1589020695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,29]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1,5]]}},"alternative-id":["22751","29416731"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.22751","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,29]]}}}